Stockscreener 앱 받기
89.72
0.02%
0.02
시장 영업 전:
89.81
0.09
+0.10%
전일 마감가:
$89.70
열려 있는:
$90.94
하루 거래량:
609.51K
Relative Volume:
0.75
시가총액:
$6.15B
수익:
$217.17M
순이익/손실:
$-202.68M
주가수익비율:
-38.96
EPS:
-2.3028
순현금흐름:
$-156.63M
1주 성능:
+2.12%
1개월 성능:
-0.88%
6개월 성능:
-20.21%
1년 성능:
+43.81%
1일 변동 폭
$88.53
$91.96
1주일 범위
$84.90
$98.37
52주 변동 폭
$60.70
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
명칭
Rhythm Pharmaceuticals Inc
전화
857-264-4280
주소
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
89.72 | 6.15B | 217.17M | -202.68M | -156.63M | -2.3028 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-19 | 개시 | RBC Capital Mkts | Outperform |
| 2025-11-25 | 개시 | Citigroup | Buy |
| 2025-11-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-07-07 | 개시 | Leerink Partners | Outperform |
| 2025-04-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-05 | 재개 | Stifel | Buy |
| 2025-01-02 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Oppenheimer | Outperform |
| 2024-10-21 | 개시 | Guggenheim | Buy |
| 2024-09-18 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-08-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 재확인 | Needham | Buy |
| 2022-03-02 | 재개 | Stifel | Buy |
| 2022-02-17 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 재개 | Goldman | Neutral |
| 2021-08-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-08-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-01-08 | 개시 | Goldman | Sell |
| 2019-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2019-07-08 | 개시 | Canaccord Genuity | Buy |
| 2019-03-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-09-07 | 재개 | Morgan Stanley | Overweight |
| 2018-06-25 | 재확인 | Needham | Buy |
| 2018-06-15 | 재확인 | Needham | Buy |
| 2017-10-30 | 개시 | BofA/Merrill | Buy |
| 2017-10-30 | 개시 | Needham | Buy |
모두보기
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Citizens reiterates Rhythm Pharmaceuticals stock rating on bivamelagon data By Investing.com - Investing.com Canada
How This Biotech Is Taking On Genetic Obesity — And Winning - Investor's Business Daily
Rhythm Showcases Positive Setmelanotide Data Across Obesity Trials - TipRanks
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026 - The Manila Times
Rhythm Pharmaceuticals (RYTM) reports strong MC4R obesity data across PWS, HO and BBS at ENDO 2026 - Stock Titan
Rhythm Pharmaceuticals Announces Multiple New Data Presentations From Mc4r Agonists - TradingView
Rhythm trial finds up to 38% BMI drop in complex rare obesity cases - Stock Titan
Why Is Rhythm Pharma Stock Jumping Today? - Benzinga
Stifel reiterates Rhythm Pharmaceuticals stock rating on PWS data By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Promising Upside Amidst Strong Buy Ratings - DirectorsTalk Interviews
Rhythm Pharmaceuticals (RYTM) Announces Positive Phase 2 Trial R - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Rhythm Pharmaceuticals reports phase 2 PWS trial results By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals reports phase 2 PWS trial results - Investing.com
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 - The Manila Times
Rhythm Pharmaceuticals Says Six-Month Data Shows Setmelanotide Improves Multiple Endpoints In Pws - TradingView
Experimental PWS drug cuts body fat and hunger in small six-month trial - Stock Titan
Rhythm Pharmaceuticals Reports Positive Phase 2 Results for PWS Treatment - Intellectia AI
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase - GlobeNewswire
Rhythm Pharmaceuticals, Inc. (RYTM) reports Q1 loss, tops revenue estimates - MSN
RYTM Technical Analysis & Stock Price Forecast - Intellectia AI
RYTM: ENDO to feature key Praloretel and RM-718 data as HO launch gains momentum in rare disease space - TradingView
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 59.95% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Long term debt to total assets ratio of Rhythm Pharmaceuticals, Inc. – XETR:1RV - TradingView
EBITDA per share of Rhythm Pharmaceuticals, Inc. – XETR:1RV - TradingView
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Updating Its Bardet-Biedl Diagnosis Algorithm - Yahoo Finance
Book value per share of Rhythm Pharmaceuticals, Inc. – XETR:1RV - TradingView
Quick ratio of Rhythm Pharmaceuticals, Inc. – XETR:1RV - TradingView
EBIT per share of Rhythm Pharmaceuticals, Inc. – XETR:1RV - TradingView
Rhythm Pharmaceuticals, Inc. Balance Sheet – XETR:1RV - TradingView
Rhythm Pharmaceuticals, Inc. Revenue Breakdown – XETR:1RV - TradingView
(RYTM) Risk Channels and Responsive Allocation - Stock Traders Daily
Rhythm Pharmaceuticals stock rating reaffirmed by Citizens - Investing.com Canada
Rhythm Pharmaceuticals: The Rare Obesity Platform Is Becoming A Commercial Engine - Seeking Alpha
Analysts Estimate Rhythm Pharmaceuticals, Inc. (RYTM) to Report a Decline in Earnings: What to Look Out for - Eastern Progress
PTC Therapeutics Drops 6.3% Amid Sector-Wide Selling - AlphaStreet
Rhythm Pharmaceuticals, Inc. (RYTM): Investor Outlook Reveals 56% Potential Upside Amid Robust Revenue Growth - DirectorsTalk Interviews
RYTM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
What Does the FDA's PDUFA Extension Signal for Rhythm Pharmaceuticals - Kavout
Rhythm Pharmaceuticals to Present Seven Abstracts at ENDO 2026, Highlighting Advances in Treatment for Rare Neuroendocrine Diseases - Quiver Quantitative
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026 - GlobeNewswire
Inside Rhythm’s seven ENDO 2026 talks on hypothalamic obesity, PWS, BBS - Stock Titan
Breakeven On The Horizon For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Moomoo
Why Rhythm Pharmaceuticals stock triumphed on Tuesday - MSN
Rhythm Pharmaceuticals Announces Publication of New - GlobeNewswire
New Bardet-Biedl diagnostic guide tackles years-long diagnosis delays - Stock Titan
(RYTM) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Rhythm Pharmaceuticals to present at major healthcare conferences in June 2026 - Pluang
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - The Manila Times
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 57% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
[Form 4] RHYTHM PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Rhythm Pharmaceuticals Inc (RYTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rhythm Pharmaceuticals Inc 주식 (RYTM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| German Christopher Paul | Corporate Controller & CAO |
May 15 '26 |
Option Exercise |
42.17 |
4,442 |
187,313 |
4,643 |
| German Christopher Paul | Corporate Controller & CAO |
May 15 '26 |
Sale |
92.21 |
4,643 |
428,131 |
0 |
| German Christopher Paul | Corporate Controller & CAO |
Mar 04 '26 |
Option Exercise |
17.97 |
1,500 |
26,955 |
5,753 |
| German Christopher Paul | Corporate Controller & CAO |
Mar 04 '26 |
Sale |
89.56 |
5,614 |
502,790 |
160 |
1.27%
1.43%
자본화:
|
볼륨(24시간):